ストックスクリーナーアプリを入手
9.62
1.48%
0.14
前日終値:
$9.48
開ける：
$9.42
24時間の取引高:
2.00M
Relative Volume:
1.71
時価総額：
$1.22B
収益：
$628.25M
当期純損益:
$-78.55M
株価収益率:
-15.52
EPS:
-0.62
ネットキャッシュフロー:
$-29.73M
1週間 パフォーマンス:
-2.43%
1か月 パフォーマンス:
-2.04%
6か月 パフォーマンス:
-33.66%
1年 パフォーマンス:
-38.80%
1日の値動き範囲:
$9.035
$9.688
1週間の範囲:
$9.035
$10.37
52週間の値動き範囲:
$9.00
$19.11
Neogenomics Inc Stock (NEO) Company Profile
NEO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
9.62 | 1.22B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
500.16 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.85 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
415.87 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.69 | 33.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
177.39 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
Where are the Opportunities in (NEO) - Stock Traders Daily
3 Reasons to Sell NEO and 1 Stock to Buy Instead - Yahoo Finance
Piper Sandler maintains Neogenomics stock with $18 target - Investing.com
Piper Sandler maintains Neogenomics stock with $18 target By Investing.com - Investing.com UK
NeoGenomics elevates Warren Stone to President and COO By Investing.com - Investing.com Australia
NeoGenomics Promotes Warren Stone to President & COO - TipRanks
Fort Myers-based NeoGenomics names new COO - Gulfshore Business
Earnings call transcript: NeoGenomics Q4 2024 results disappoint despite EPS beat - Investing.com
NeoGenomics elevates Warren Stone to President and COO - Investing.com
NeoGenomics Names Warren Stone President, COO -March 18, 2025 at 08:09 am EDT - Marketscreener.com
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer - Lelezard
NeoGenomics Appoints Warren Stone As President & Chief Operating Officer -March 18, 2025 at 07:10 am EDT - Marketscreener.com
Commit To Buy NeoGenomics At $8, Earn 19.6% Annualized Using Options - Nasdaq
SBI Securities Co. Ltd. Invests $26,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics at Barclays Healthcare: Strategic Focus on Innovation - Investing.com India
Bank of New York Mellon Corp Purchases 15,269 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.60 Average Target Price from Analysts - Defense World
NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth By Investing.com - Investing.com South Africa
(NEO) Technical Pivots with Risk Controls - Stock Traders Daily
NeoGenomics at Leerink Global Healthcare: Strategic Transition and Growth - Investing.com
Fort Myers-based NeoGenomics expands cancer testing reach with acquisition - News-Press
Proficio Capital Partners LLC Invests $372,000 in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
BTIG maintains $17 target on Neogenomics stock post-acquisition By Investing.com - Investing.com UK
NeoGenomics Acquires Pathline -March 10, 2025 at 08:13 am EDT - Marketscreener.com
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - BioSpace
NeoGenomics expands with Pathline acquisition - Investing.com India
NeoGenomics expands with Pathline acquisition By Investing.com - Investing.com South Africa
NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline - Marketscreener.com
Smartleaf Asset Management LLC Has $70,000 Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics Acquires Pathline Lab to Dominate Northeast Market - StockTitan
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) - ACCESS Newswire
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors - Simply Wall St
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
NeoGenomics price target lowered to $17 from $18 at BTIG - MSN
NeoGenomics at TD Cowen Conference: CEO Transition and Growth Plans By Investing.com - Investing.com UK
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Truist Financial Corp - Defense World
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes - ACCESS Newswire
NeoGenomics Announces Leadership Team Transition - ACCESS Newswire
Investor Network Invites You to the NeoGenomics First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, April 26, 2017 - ACCESS Newswire
Principal Financial Group Inc. Acquires 18,455 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics (NASDAQ:NEO) Sets New 52-Week LowTime to Sell? - MarketBeat
NeoGenomics To Virtually Participate In Fireside Chat At The 40th Annual William Blair Growth Stock Conference - ACCESS Newswire
NeoGenomics To Virtually Participate In Fireside Chat At The Stephens Annual Investment Conference 2020 - ACCESS Newswire
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference - ACCESS Newswire
NeoGenomics Schedules its Second Quarter Earnings Release for July 30, 2019 - ACCESS Newswire
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences - ACCESS Newswire
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences - ACCESS Newswire
NeoGenomics: Decent Fundamentals, But Still Overvalued - Seeking Alpha
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results - ACCESS Newswire
NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter - ACCESS Newswire
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2019 Earnings Release for February 27, 2020 - ACCESS Newswire
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
Neogenomics Inc (NEO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Harris Melody | Chf Ops Off, Pres, Informatics |
Feb 23 '25 |
Option Exercise |
0.00 |
8,443 |
0 |
111,811 |
| Stone Warren | Chief Commerical Officer |
Feb 23 '25 |
Option Exercise |
0.00 |
8,443 |
0 |
93,265 |
| Sherman Jeffrey Scott | Chief Financial Officer |
Feb 23 '25 |
Option Exercise |
0.00 |
15,535 |
0 |
141,271 |
| Smith Christopher M | Chief Executive Officer |
Feb 23 '25 |
Option Exercise |
0.00 |
57,413 |
0 |
655,652 |
| Olivo Alicia C | General Counsel |
Nov 15 '24 |
Sale |
15.36 |
5,175 |
79,475 |
37,129 |
0.80%
0.71%
大文字化:
|
ボリューム (24 時間):